Study of durvalumab and olaparib for endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how well two drugs, durvalumab and olaparib, work together after initial chemotherapy for advanced or recurrent endometrial cancer. It may help patients who have not had many treatment options before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 18 years or older.
- You have advanced (stage III or IV) or recurrent endometrial cancer, including a type called carcinosarcoma.
- You are about to start or have already started a specific chemotherapy (carboplatin and paclitaxel) for your cancer, but have had no more than 2 cycles.
- Your doctor plans to give you durvalumab (with or without olaparib) after chemotherapy, based on your tumor's MMR (mismatch repair) status.
- You can fill out questionnaires about your health in German, English, Arabic, Russian, or Turkish.
- You are not pregnant or breastfeeding, and do not have allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects safety information on the standard use of Durvalumab (with or without Olaparib) in people with endometrial cancer in Korea. It helps doctors confirm the real-world effects of these approved treatments.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
This study tests whether olaparib and durvalumab given around the time of diagnosis can help people with advanced ovarian cancer. It also strongly focuses on collecting tumor and blood samples to better understand who may benefit.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.